Angiotensin II promotes iron accumulation and depresses PGI2 and NO synthesis in endothelial cells: Effects of losartan and propranolol analogs

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 10, 2012, Pages 1413-1418

  Mak, I Tong ^a   Landgraf, Kenneth M ^a   Chmielinska, Joanna J ^a   Weglicki, William B ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Angiotensin II; D propranolol; Endothelial cell iron accumulation; Lysosomotropic properties; Oxidative stress and dysfunction

Indexed keywords

2'7' DICHLOROFLUORESCEIN DIACETATE; 4 HO PROPANOLOL; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATENOLOL; DEXPROPRANOLOL; DEXTRO LEVO PROPANOLOL; FLUORESCEIN DIACETATE; GLUTATHIONE; LOSARTAN; METHYLAMINE; NITRIC OXIDE; PROPRANOLOL DERIVATIVE; PROSTACYCLIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FLUORESCENCE ANALYSIS; IRON STORAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; REACTION TIME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; CATTLE; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; GLUTATHIONE; IRON; IRON OVERLOAD; LOSARTAN; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROPRANOLOL; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84868155784     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-104     Document Type: Article

References (23)

1. Brissot, P., Ropert, M., Le Lan, C., and Loreal, O. 2011. Nontransferrin bound iron: A key role in iron overload and iron toxicity. Biochim. Biophys. Acta, 1820(3): 403-410. PMID:21855608.
2. Cramb, G. 1986. Selective lysosomal uptake and accumulation of the b-adrenergic antagonist propranolol in cultured and isolated cell systems. Biochem. Pharmacol. 35(8): 1365-1372. doi:10.1016/0006-2952(86)90283-2. PMID:3008762.
3. Dickens, B.F., Weglicki, W.B., Boehme, P.A., and Mak, I.T. 2002. Antioxidant and lysosomotropic properties of acridine-propranolol: protection against oxidative endothelial cell injury. J. Mol. Cell. Cardiol. 34(2): 129-137. doi:10.1006/jmcc.2001.1495. PMID:11851353.
4. Gaenzer, H., Marschang, P., Sturm, W., Neumayr, G., Vogel, W., Patsch, J., and Weiss, G. 2002. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J. Am. Coll. Cardiol. 40(12): 2189-2194. doi:10.1016/S0735-1097(02)02611-6. PMID:12505233.
5. Grootveld, M., Bell, J.D., Halliwell, B., Aruoma, O.I., Bomford, A., and Sadler, P.J. 1989. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 264(8): 4417-4422. PMID:2466835.
6. Hein, T.W., Qamirani, E., Ren, Y., and Kuo, L. 2009. C-reactive protein impairs coronary arteriolar dilation to prostacyclin synthase activation: role of peroxynitrite. J. Mol. Cell. Cardiol. 47(2): 196-202. doi:10.1016/j.yjmcc.2009.04.015. PMID:19410579.
7. Ishizaka, N., Saito, K., Mitani, H., Yamazaki, I., Sata, M., Usui, S., et al. 2002. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation, 106(14): 1840-1846. doi:10.1161/01.CIR.0000031161.77536.02. PMID:12356639.
8. Ishizaka, N., Saito, K., Noiri, E., Sata, M., Ikeda, H., Ohno, M., and Nagai, R. 2005a. Administration of Ang II induces iron deposition and upregulation of TGF-b1 mRNA in the rat liver. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288(4): R1063-R1070. PMID:15604307.
9. Ishizaka, N., Saito, K., Mori, I., Matsuzaki, G., Ohno, M., and Nagai, R. 2005b. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin IIinfused rats. Arterioscler. Thromb. Vasc. Biol. 25(11): 2282-2288. doi:10.1161/01.ATV.0000181763.57495.2b. PMID:16100038.
10. Jaimes, E.A., Hua, P., Tian, R.X., and Raij, L. 2010. Human glomerular endothelium: interplay amongglucose, free fatty acids, Angiotensin II, and oxidative stress. Am. J. Physiol. Renal Physiol. 298(1): F125-F132. doi:10.1152/ajprenal.00248.2009. PMID:19864304.
11. Kreeftenberg, H.G., Koopman, B.J., Huizenga, J.R., van Vilsteren, T., Wolthers, B.G., and Gips, C.H. 1984. Measurement of iron in biopsies - a comparison of three analytical methods. Clin. Chim. Acta, 144(2-3): 255-262. doi:10.1016/0009-8981(84)90061-5. PMID:6529859.
12. Mak, I.T., and Weglicki, W.B. 2004. Potent antioxidant properties of 4-hydroxyl-propranolol. J. Pharmacol. Exp. Ther. 308(1): 85-90. doi:10.1124/jpet.103.058032. PMID:14569064.
13. Mak, I.T., Boehme, P.A., and Weglicki, W.B. 1995. Protective effects of calcium channel blockers against free radical-impaired endothelial cell proliferation. Biochem. Pharmacol. 50(9): 1531-1534. doi:10.1016/0006-2952(95)02039-X. PMID:7503807.
14. Mak, I.T., Komarov, A.M., Wagner, T.L., Stafford, R.E., Dickens, B.F., and Weglicki, W.B. 1996. Enhanced NO production during Mg deficiency and its role in mediating red blood cell glutathione loss. Am. J. Physiol. 271(1): C385-C390. PMID:8760069.
15. Mak, I.T., Chmielinska, J.J., Nedelec, L., Torres, A., and Weglicki, W.B. 2006. D-Propranolol attenuates lysosomal iron accumulation and oxidative injury in endothelial cells. J. Pharmacol. Exp. Ther. 317(2): 522-528. doi:10.1124/jpet.105.097709. PMID:16456084.
16. Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., et al. 2002. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J. Am. Soc. Nephrol. 13(10): 2478-2487. doi:10. 1097/01.ASN.0000032418.67267.F2. PMID:12239236.
17. Oatis, J.E., Jr, Russell, M.P., Knapp, D.R., and Walle, T. 1981. Ringhydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. J. Med. Chem. 24 (3): 309-314. doi:10.1021/jm00135a014. PMID:6115057.
18. Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T., and Evans, P. 2005. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann. N. Y. Acad. Sci. 1054 (1): 155-168. doi:10.1196/annals.1345.018. PMID:16339661.
19. Salvador, G.A., and Oteiza, P.I. 2011. Iron overload triggers redoxsensitive signals in human IMR-32 neuroblastoma cells. Neurotoxicology, 32(1): 75-82. doi:10.1016/j.neuro.2010.11.006. PMID:21130806.
20. Scheiber-Mojdehkar, B., Lutzky, B., Schaufler, R., Sturm, B., and Goldenberg, H. 2004. Non-transferin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J. Am. Soc. Nephrol. 15(6): 1648-1655. doi:10.1097/01.ASN.0000130149.18412.56. PMID:15153577.
21. Solheim, A.E., and Seglen, P.O. 1983. Cellular and lysosomal uptake of methylamine in isolated rathepatocytes. Biochem. J. 210(3): 929-936. PMID:6870811.
22. Tajima, S., Tsuchiya, K., Horinouchi, Y., Ishizawa, K., Ikeda, Y., Kihira, Y., et al. 2010. Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells. Hypertens. Res. 33(7): 713-721. doi:10.1038/hr.2010.63. PMID:20431588.
23. Zhang, H., Schmeiber, A., Garlichs, C.D., Plötze, K., Damme, U., Mügge, A., et al. 1999. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membranebound NADH/NADPH-oxidase. Cardiovasc. Res. 44(1): 215-222. doi:10.1016/S0008-6363(99)00183-2. PMID:10615405.